This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes


Weintraub, Daniel, Rosenberg, Paul B., Drye, Lea T., Martin, Barbara K., Frangakis, Constantine, Mintzer, Jacobo E., Porsteinsson, Anton P., Schneider, Lon S., Rabins, Peter V., Munro, Cynthia A., Meinert, Curtis L., Lyketsos, Constantine G.


The American Journal Of Geriatric Psychiatry: Official Journal Of The American Association For Geriatric Psychiatry, Volume: 18, No.: 4, Pages.: 332-340

Year of Publication



Background: Depression and antidepressant use are common in Alzheimer disease (AD), but the effect of antidepressant treatment for depression on longer term outcomes is unknown. The authors report the Week-24 outcomes of patients who participated in a 12-week efficacy study of sertraline for depression of AD.; Methods: One hundred thirty-one participants (sertraline = 67, placebo = 64) with mild-moderate AD and depression participated in the study. Patients who showed improvement on the modified Alzheimer’s Disease Cooperative Study Clinical Global Impression-Change (mADCS-CGIC) after 12 weeks of randomized treatment with sertraline or placebo continued double-blinded treatment for an additional 12 weeks. Depression response and remission at 24 weeks were based on mADCS-CGIC score and change in Cornell Scale for Depression in Dementia (CSDD) score. Secondary outcome measures included time to remission, nonmood neuropsychiatric symptoms, global cognition, function, and quality of life.; Results: One hundred seventeen (89.3%) participants completed all study assessments and 74 (56.5%; sertraline = 38, placebo = 36) completed all 24 weeks on randomized treatment. By 24 weeks, there were no between-group differences in depression response (sertraline = 44.8%, placebo = 35.9%; odds ratio [95% CI] = 1.23 [0.64-2.35]), change in CSDD score (median difference = 0.6 [95% CI: -2.26 to 3.46], chi2 [df = 2] = 1.03), remission rates (sertraline = 32.8%, placebo = 21.8%; odds ratio [95% CI] = 1.61 [0.70-3.68]), or secondary outcomes. Common selective serotonin reuptake inhibitor-associated adverse events, specifically diarrhea, dizziness, and dry mouth, and pulmonary serious adverse events were more frequent in sertraline-randomized patients than in placebo subjects.; Conclusions: Sertraline treatment is not associated with delayed improvement between 12 and 24 weeks of treatment and may not be indicated for the treatment of depression of AD.;

Bibtex Citation

@article{Weintraub_2010, doi = {10.1097/jgp.0b013e3181cc0333}, url = {}, year = 2010, month = {apr}, publisher = {Elsevier {BV}}, volume = {18}, number = {4}, pages = {332--340}, author = {Daniel Weintraub and Paul B. Rosenberg and Barbara K. Martin and Constantine Frangakis and Jacobo E. Mintzer and Anton P. Porsteinsson and Lon S. Schneider and Cynthia A. Munro and Curtis L. Meinert and Constantine G. Lyketsos and Lea T. Drye and Peter V. Rabins}, title = {Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24 Outcomes}, journal = {The American Journal of Geriatric Psychiatry} }


activities of daily living, adverse effects, aged, alzheimer disease, antidepressive agents, cognition disorders, complications, depression, diagnosis, drug therapy, female, geriatric assessment, humans, male, mental disorders, patient compliance, quality of life, sertraline, statistics & numerical data, therapeutic use

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

ADLs/IADLs, Cognition, Depression and Anxiety, Quality of Life of Person With Dementia

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Antipsychotics and antidepressants